People with advanced skin cancer should be able to receive ipilimumab as a first treatment, the National Institute for Health and Care Excellence (NICE) proposes.
In final draft guidance, NICE recommends that the drug ipilimumab (also called Yervoy and manufactured by Bristol-Myers Squibb Pharmaceuticals Limited) is made available on the NHS as a first-line treatment for patients with advanced malignant melanoma which is either unresectable (when the full tumour cannot be removed) or metastatic (the cancer has spread to other parts of the body).
Sir Andrew Dillon, NICE chief executive, said: “We already recommend ipilimumab as a second-line treatment and so we are pleased to be able to propose extending that recommendation to first line treatment too.
Press release: http://bit.ly/1ueXQc1
Source: NICE
NCCN Launches Pilot Project Aiming to Measure, Implement Health Equity in Cancer Care Practices
February 4th 2023Five leading academic cancer centers are assessing the feasibility of implementing the Health Equity Report Card pilot project as a tool that can both meaningfully and feasibly measure and report on equitable care practices.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Study Suggests MRI Is the Best Breast Cancer Screening Modality for Dense Breasts
February 1st 2023A review and meta-analysis published in the journal Radiology found MRI to be the most effective supplemental breast cancer screening method for women with dense breasts and negative mammogram results.
Read More
Interstitial Lung Abnormalities Impact OS in NSCLC Patients Receiving CRT, Adjuvant Durvalumab
January 19th 2023Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512